News & Updates
Filter by Specialty:
Use of a MET inhibitor in a patient with newly diagnosed advanced NSCLC with METex14 skipping mutation
An 80-year-old Chinese male, a long-term smoker with no signifÂicant medical history, was found to have a right lung mass on a routine chest X-ray in August 2021. A CT scan of the chest revealed a domiÂnant right lower lobe mass (3.3 x 2.3 x 2.7 cm) with multiple bilateral lung nodules. CT-guided fine needle aspiration cytology (FNAC) of the right lower lobe mass performed on 2 December 2021 confirmed adenoÂcarcinoma, while a PET-CT scan on 10 January 2022 showed a right lowÂer lobe tumour with metastases to the left hilar and mediastinal lymph nodes and both lungs. (Figure 1A) Next-generation sequencing (OncoSnap Nonet) identified MET exon 14 (MEÂTex14) skipping mutation. The proÂgrammed death ligand 1 (PD-L1) tumour proportion score (TPS) was 0 percent. The patient was diagnosed with stage IV non-small-cell lung canÂcer (NSCLC) harbouring a METex14 skipping mutation. His Eastern CoopÂerative Oncology Group performance status (ECOG PS) was 0.
Use of a MET inhibitor in a patient with newly diagnosed advanced NSCLC with METex14 skipping mutation
23 Oct 2025
Polygenic risk score shows promise in predicting future breast cancer events
A retrospective analysis shows the potential of the 313-SNP breast cancer (BC) polygenic risk score (PRS313) blood test to predict future in situ or invasive breast disease in women diagnosed with ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).
